Top Suppliers:I want be here


46868-19-3

46868-19-3 structure
46868-19-3 structure
  • Name: N-Desmethylnefopam
  • Chemical Name: 1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine
  • CAS Number: 46868-19-3
  • Molecular Formula: C16H17NO
  • Molecular Weight: 239.31200
  • Catalog: Research Areas Neurological Disease
  • Create Date: 2017-10-23 10:06:10
  • Modify Date: 2024-01-02 20:59:33
  • N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2][3].

Name 1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine
Synonyms desmethyl nefopam
nor-nefopam
1H-2,5-Benzoxazocine,3,4,5,6-tetrahydro-1-phenyl
Description N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2][3].
Related Catalog
References

[1]. Mittur A. A Simultaneous Mixed-Effects Pharmacokinetic Model for Nefopam, N-desmethylnefopam, and Nefopam N-Oxide in Human Plasma and Urine. Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):391-404.

[2]. Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11.

[3]. Baht GS, et al. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone. 2017 May;98:31-36.

Density 1.073g/cm3
Boiling Point 383.4ºC at 760 mmHg
Molecular Formula C16H17NO
Molecular Weight 239.31200
Flash Point 157.1ºC
Exact Mass 239.13100
PSA 21.26000
LogP 3.22460
Index of Refraction 1.563

~85%

46868-19-3 structure

46868-19-3

Literature: Rosamilia, Anthony E.; Mayes, Penelope A.; Papadopoulos, Roslyn; Campi, Eva M.; Jackson, W. Roy; Rash, Lachlan; Jarrott, Bevyn Australian Journal of Chemistry, 2002 , vol. 55, # 9 p. 577 - 585

~10%

46868-19-3 structure

46868-19-3

Literature: Rosamilia, Anthony E.; Mayes, Penelope A.; Papadopoulos, Roslyn; Campi, Eva M.; Jackson, W. Roy; Rash, Lachlan; Jarrott, Bevyn Australian Journal of Chemistry, 2002 , vol. 55, # 9 p. 577 - 585

~%

46868-19-3 structure

46868-19-3

Literature: Glaser; Geresh; Blumenfeld; Donnell; Sugisaka; Drouin; Michel Journal of Pharmaceutical Sciences, 1993 , vol. 82, # 3 p. 276 - 281

~%

46868-19-3 structure

46868-19-3

Literature: Glaser; Geresh; Blumenfeld; Donnell; Sugisaka; Drouin; Michel Journal of Pharmaceutical Sciences, 1993 , vol. 82, # 3 p. 276 - 281

~%

46868-19-3 structure

46868-19-3

Literature: Glaser; Geresh; Blumenfeld; Donnell; Sugisaka; Drouin; Michel Journal of Pharmaceutical Sciences, 1993 , vol. 82, # 3 p. 276 - 281

~%

46868-19-3 structure

46868-19-3

Literature: Glaser; Geresh; Blumenfeld; Donnell; Sugisaka; Drouin; Michel Journal of Pharmaceutical Sciences, 1993 , vol. 82, # 3 p. 276 - 281

~%

46868-19-3 structure

46868-19-3

Literature: Rosamilia, Anthony E.; Mayes, Penelope A.; Papadopoulos, Roslyn; Campi, Eva M.; Jackson, W. Roy; Rash, Lachlan; Jarrott, Bevyn Australian Journal of Chemistry, 2002 , vol. 55, # 9 p. 577 - 585

~%

46868-19-3 structure

46868-19-3

Literature: Rosamilia, Anthony E.; Mayes, Penelope A.; Papadopoulos, Roslyn; Campi, Eva M.; Jackson, W. Roy; Rash, Lachlan; Jarrott, Bevyn Australian Journal of Chemistry, 2002 , vol. 55, # 9 p. 577 - 585